IR
TEVA icon

Invictus RG’s Teva Pharmaceuticals TEVA Stock Holding History

Invictus RG’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,945
Closed -$104K – 723
2016
Q1 		$104K Sell
1,945
-3,329
-63% -$195K 0.13% 287
2015
Q4 		$346K Buy
+5,274
New +$326K 0.33% 98

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invictus RG's TEVA Position: Q2 2016 in Review

Invictus RG sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 1,945 shares — an estimated $104K sold.

Invictus RG first reported a position in TEVA in Q4 2015 and held it in 2 quarters. The position peaked at $346K in Q4 2015. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

  • Invictus RG reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Invictus RG sold 1,945 Teva Pharmaceuticals shares in Q2 2016, an estimated $104K.
  • Invictus RG first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Invictus RG's Teva Pharmaceuticals position peaked at $346K in Q4 2015.
  • 812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Invictus RG's 13F filing for Q2 2016, filed 15 Aug 2016.